Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...
BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...
Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...
MacroGenics, Inc.’s MGNX share price has dipped by 14.19%, which has investors questioning if this is right time to buy.
This is anticipated to enable safer anti-CTLA-4 antibody combination therapies, such as with anti-PD-1 antibody checkpoint inhibitors, and potentially broaden the patient population tolerant to ...
BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback